Post‐adenoviral‐based COVID‐19 vaccines thrombosis: A proposed mechanism
K Kadkhoda - Journal of Thrombosis and Haemostasis, 2021 - jthjournal.org
There have been several reports of thrombosis and thrombocytopenia after vaccination with
the ChAdOx1 nCoV-19 vaccine (Oxford–Astra-Zeneca) and Ad26. COV2. S vaccine
(Johnson & Johnson/Janssen), a recombinant adenovirus serotype 26 vector encoding the
SARS-CoV-2 spike glycoprotein. 1, 2 These cases clinically manifest as disseminated
intravascular coagulation-like phenomena. Recently anti-platelet factor 4 (PF4)
autoantibodies detected by ELISAs were deemed as the number one culprit, but this finding …
the ChAdOx1 nCoV-19 vaccine (Oxford–Astra-Zeneca) and Ad26. COV2. S vaccine
(Johnson & Johnson/Janssen), a recombinant adenovirus serotype 26 vector encoding the
SARS-CoV-2 spike glycoprotein. 1, 2 These cases clinically manifest as disseminated
intravascular coagulation-like phenomena. Recently anti-platelet factor 4 (PF4)
autoantibodies detected by ELISAs were deemed as the number one culprit, but this finding …